Alzamend Neuro, Inc. ALZN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 86.19% | 66.68% | 10.76% | -4.98% | 6.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.83% | 94.96% | 67.18% | 0.76% | -15.45% |
| Operating Income | -45.83% | -94.96% | -67.18% | -0.76% | 15.45% |
| Income Before Tax | -45.71% | -94.30% | -66.60% | -0.55% | 15.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.71% | -94.30% | -66.60% | -0.55% | 15.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.71% | -94.30% | -66.60% | -0.55% | 15.57% |
| EBIT | -45.83% | -94.96% | -67.18% | -0.76% | 15.45% |
| EBITDA | -45.59% | -94.69% | -66.92% | -0.25% | 15.76% |
| EPS Basic | 74.21% | 84.81% | 83.96% | 90.61% | 90.86% |
| Normalized Basic EPS | 71.78% | 84.17% | 86.47% | 91.88% | 91.65% |
| EPS Diluted | 74.21% | 84.81% | 83.96% | 90.61% | 90.86% |
| Normalized Diluted EPS | 71.78% | 84.17% | 86.47% | 91.88% | 91.65% |
| Average Basic Shares Outstanding | 309.06% | 635.69% | 758.03% | 977.08% | 1,121.65% |
| Average Diluted Shares Outstanding | 309.06% | 635.69% | 758.03% | 977.08% | 1,121.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |